Breast cancer 1, early onset (*BRCA1*) is one of the most important genes in human familial breast and ovarian cancers. Human *BRCA1* was first identified in 1994 by positional cloning methods \[[@r17]\]. The role of the BRCA1 protein is implicated in vital cellular functions. As a tumor suppressor, BRCA1 in association with RAD51 takes part in the repair of DNA double-strand breaks (DSBs) \[[@r19], [@r23]\]. BRCA1 is involved in maintaining heterochromatin integrity by regulating the ubiquitylation of histone H2A \[[@r35]\]. BRCA1 is known to induce apoptosis in human breast cancer cell lines \[[@r24]\]. Induction of BRCA1 triggers apoptosis through activation of c-Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) \[[@r9]\]. The human BRCA1 C-terminal (BRCT) region (amino acids 1560-1863) is recognized as a transcriptional activator in mammalian cells \[[@r18]\]. The integrity of the BRCT domains of BRCA1 is crucial for its role in activating transcription \[[@r10]\]. The importance of BRCA1 in the regulation of translation is also recognized. Inhibition of endogenous BRCA1 by using a small interfering RNA-based approach decreased protein synthesis and overexpression of BRCA1 activated translation, both of which suggested that BRCA1 modulated protein synthesis \[[@r4]\]. BRCA1 regulates the key effectors that control the G2/M checkpoint and is therefore believed to be involved in regulating the onset of mitosis \[[@r30], [@r31]\].

The well-known function of BRCA1 is its role in mammary tumorigenesis. By age 70, *BRCA1*-mutation carrying individuals demonstrated 87% cumulative risk for the occurrence of breast cancer \[[@r8]\]. In a study, the prevalence rate of BRCA1 mutation in the patients under 55 was 0.7% \[[@r2]\]. Besides germ line mutation, decreased expression of BRCA1 is an important cause of tumorigenesis in human sporadic cases \[[@r28]\]. DNA methylation of this gene is one of the principle mechanisms for silencing BRCA1 \[[@r6]\].

In 1996, the coding sequence of canine BRCA1 mRNA was determined \[[@r26]\]. Similar to humans, genetic variations in *BRCA1* were significantly associated with canine mammary tumors \[[@r21]\]. Extensive studies have been reported to identify the function and mutational status of *BRCA1* in human breast cancer. However, only limited data are available on the mutational status in the coding region and the DNA methylation of BRCA1 in canine mammary tumors. The objectives of the present study are to determine the mutational status of the canine *BRCA1* coding region and to detect the methylation status of the 5′ flanking region of canine *BRCA1* in canine mammary tumors.

MATERIALS AND METHODS {#s1}
=====================

Sample collection
-----------------

*All the canine tissue samples obtained from the Animal Hospital of China Agriculture University were divided into three groups*: normal canine mammary tissue group (*n*=10), benign canine mammary tumor group (*n*=15) and malignant canine mammary tumor group (*n*=15). All samples were verified and histopathologically diagnosed by pathologists of the Animal Hospital of China Agriculture University. The study was approved by the Animal Welfare Committee of the Department of Clinical Veterinary Medicine of China Agricultural University.

DNA extraction
--------------

Genomic DNA was extracted from mammary tissue samples using Tiangen DNA extracting Kit (Tiangen Co., Beijing, China). All DNA samples were quantified using the NanoDrop 2000 spectrophotometer (Thermo Fisher Scientific, Beijing, China). DNA samples with OD 260/280 within 1.8--2.0 were used for the study.

Sequencing the coding region of BRCA1
-------------------------------------

In order to amplify the entire coding sequence of canine *BRCA1*, the primers flanking each of the exons were designed (GenBank Accession No. NC_006591 and NM_001013416). The primers used for amplification and sequencing are listed in [Table 1](#tbl_001){ref-type="table"}Table 1.Primer sequences used for PCR and sequencingPrimer numberPrimers sequenceSizesCoding exonsExtension time1F:AAGTGATGTGTGTGTAGGCAT\
R:TATCCTGGATTTCCAAAGCTC331 bp130 sec2F: GTTTGTTGTCTTCATGGAGTGT\
R: GAGGCAGAATTACAGAGTTAG564 bp240 sec3F: GCATGTAAGCTCAGTTTTCATAG\
R: CTAATACCTTCATAAGACAGACT501 bp340 sec4F: GAGCCTACAAGAAAGTACAAGA\
R: CAAGGTAGGGTTTTCAGGTTCA1,022 bp4, 51 min 10 sec5F: CCTGGAGTTTCTCTTCAAG\
R: CCAATTCAATGTAGACAGAC182 bp630 sec6F: GCTCTGATTCAAACTTAGGA\
R: ATACTACTGTGCTTGAGGAAC520 bp740 sec7F: TCCTGTTGCCCTTCCATAAAG\
R: TCAGCCTTGTGTCATTGAAAC511 bp840 sec8F: GGGAGTATGAGTCTGAGGATAGAAC\
R: ATATGATAAGGGTTTTGGGAAATTC2,598 bpPart of exon 92 min 30 sec9F: AAGCTAAGAAGCCAGGCGATTTTGC\
R: CTCTGTAGGCTCCAATTTGGTCCCA2,176 bpPart of exon 9 and exon 102 min 30 sec10F: CAGAGAGATACCATGCAAGATAAC\
R: CTCTTTCTGATGCGTTTTGTTCCG172 bp1130 sec11F: AGCCTCGTCTCAGCCAAGTAT\
R: TCTCATCTCATAGCTCATGCC588 bp1240 sec12F: TGAAAAATATCCCACCTCAGC\
R: AGCACACAAGACTCTCCCAT654 bp1350 sec13F: GGTCATAAAACAGTTGGAGAAC\
R: CTTTAGCTTTATCTAGGTCCCA697 bp1450 sec14F: GTGAGCACAGACTATTTTAG\
R: CACTACTCTCCAAATCTTAACC479 bp1530 sec15F: ATGCTGAGTTTGTGTGCGAACGA\
R: GAGTACCTACCTCATCTAGTATC660 bp16, 1750 sec16F: AGTCTCAATGAGGTGAAAAG\
R: TTGGGCTTGGTCTCTCAAAT549 bp1840 sec17F: CGATGTTCTGATATTAGACTC\
R: GCACAGGGCTGTTTTTTTGAT423 bp1930 sec18F: TAGAGGGTCCAGGTCAAGTG\
R: ACAGGTACACCATCTACTCC683 bp20, 2150 sec19F: CGTGCTCCTGGTGACTTTTC\
R: AGTAACTGGGACTGTGGAAG502 bp2240 secSequencing primersSequencing primer 1: CTGAAATCAGACATGGAGAGSequencing primer 2: AAGGCATCAACAGTTAGCTCBisulfite primersF: TTTAGGGAAAGAATTGATGATTAAT\
R: TACCCTCACTCAAAAAAACCTTAAC217 bp30 sec. All 22 coding exons were separated into 19 fragments and then amplified. All of the forward and reverse primers used in PCR were used in sequencing. In addition, the sequencing primers 1 and 2 were added to sequence fragments 8 and 9, respectively. For PCR, the initial denaturation was at 95°C for 4 min, followed by 35 cycles at 94°C for 30 sec, 55°C for 30 sec, 72°C for 30 sec to 2 min 30 sec, were followed by a final elongation step at 72°C for 10 min. For each PCR reaction, 100 *n*g genomic DNA was used as template. The total volume of each reaction mixture was 25 *µl*. The extension time of each primer pair is listed in [Table 1](#tbl_001){ref-type="table"}. The amplified DNA fragments were then separated by agarose gel electrophoresis and purified using the Agarose Gel DNA Extraction Kit (Tiangen Co.) as per the manufacturer's protocol. The purified PCR products were sent to Beijing Genome Institution (Beijing, China) for sequencing, and the Sanger sequencing methods were used. All the experiments were performed in triplicates.

Predicting the effects of mutations and the altered amino acids
---------------------------------------------------------------

In order to predict the effects of mutations and the corresponding substituted amino acids, the server PolyPhen was used \[[@r1], [@r3]\] which was available at http://genetics.bwh.harvard.edu/pph2/index.shtml \[[@r1]\]. The predicted effect of a substitution was reported as unknown, benign, possibly damaging and probably damaging.

Exploring the CpG islands in the 5′ flanking region of BRCA1 and design of methylation primers
----------------------------------------------------------------------------------------------

The 1,907 bp DNA sequence in the 5′ flanking region present upstream of the *BRCA1* coding region was used to search for CpG islands. The sequence was from 19959003 to 19960909 on canine chromosome 9. CpG islands of the region were analyzed using the website "CpG Island Searcher" \[[@r27]\] available at http://cpgislands.usc.edu/. For "CpG Island Searcher", the following criteria were used: GC% \>55%; ObsCpG/ExpCpG \>0.65; length \>500 bp; and gap between adjacent islands \>100 bp. Through the "CpG Island Searcher", one CpG island was found ([Fig. 1A and 1B](#fig_001){ref-type="fig"}Fig. 1.CpG islands in the 5′ flanking region of canine *BRCA1* and bisulfite primers used for methylation analysis. Panel A: results of "CpG Island Searcher". The bold line shows the CpG island in the 5′ flanking region of canine *BRCA1*. Numbers in panel A indicate the position of corresponding nucleotides relative to translation start (ATG). Panel B: CpG island sequence and bisulfite primer position. The complete sequence in panel B shows the CpG island sequence; position of every nucleotide relative to translation start (ATG) is shown. Capital letters indicate the region amplified by bisulfite PCR. Bold capital letters indicate the position of bisulfite primers. Panel C: partial results of "MethPrimer". The primer pair "F1" and "R1" was used in the present study. Numbers in panel C indicate the position of corresponding nucleotides relative to translation start (ATG).). This CpG island started from 467 bp, ended at 1091 bp of the input sequence and was used for designing primers.

For designing bisulfite primers, the website "MethPrimer" \[[@r15]\] available at http://www.urogene.org/methprimer/ was used. The search results are illustrated in [Fig. 1B and 1C](#fig_001){ref-type="fig"} Bisulfite primers are listed in [Table 1](#tbl_001){ref-type="table"}.

Methylation analysis of the CpG island
--------------------------------------

Methylation status of the CpG island was analyzed using a modified DNA bisulfite protocol \[[@r7], [@r34]\]. DNA samples were denatured in 0.2 M NaOH at 37°C for 10 min. Sodium bisulfite was added to a final concentration of 3.0 M and hydroquinone to a final concentration of 0.5 mM, followed by incubation at 55°C for 16 hr. DNA samples were then desalted by the DNA Clean-Up System (Promega, Madison, WI, U.S.A.) followed by desulfonation in 0.3 M NaOH and ethanol-precipitation.

For PCR, the initial denaturation was at 95°C for 4 min, followed by 40 cycles at 94°C for 30 sec, 53°C for 30 sec, 72°C for 30 sec, was followed by a final elongation at 72°C for 10 min. After PCR, the amplified DNA fragments were separated by agarose gel electrophoresis and purified using gel recovery kit. The purified PCR products were then ligated with pMD-18T vectors (Takara Co., Dalian, China). After amplification in *Escherichia coli*, the plasmids were isolated and sequenced by Beijing Genome Institution. Three clones from each sample were selected for sequencing.

RESULTS {#s2}
=======

Point mutations detected in canine BRCA1 tumor samples
------------------------------------------------------

All of the 19 fragments of the *BRCA1* coding region were amplified ([Fig. 2](#fig_002){ref-type="fig"}Fig. 2.PCR results of different *BRCA1* exons. M: DNA molecular weight marker. Lanes 1--19 indicate fragments amplified by primer pairs 1--19. Sizes of amplified fragments were as expected.). Sequencing of these PCR products yielded the sequence of each fragment of each sample through assemble program of Vector NTI Suite 7. In alignment with the reference sequence (GenBank Accession No. NC_006591 and NM_001013416), varied mutation sites were found in one benign and in one malignant canine mammary tumor sample. In the benign mammary tumor sample, two point mutations were found (4702G \>T and 4765G \>T). The 4702G \>T mutation resulted in the termination of translation that truncated the BRCA1 protein. The physical effect of the 4765G \>T mutation was found to be the repalacement of the glutamate residue with glutamine. In the malignant mammary tumor sample, two point mutations were found (3619A \>G and 4006G \>A). The 3619A \>G mutation inserted an alanine residue (T1207A) instead of a threonine, and the 4006G \>A mutation inserted an isoleucine residue (V1336I) instead of valine in the BRCA1 polypeptide.

Effects of amino acids substitutions on the function of the BRCA1 protein
-------------------------------------------------------------------------

The effects of the three nonsynonymous point mutations on the function of the BRCA1 protein were predicted by PolyPhen. The results are listed in [Table 2](#tbl_002){ref-type="table"}Table 2.Prediction of functional effects of the three nonsynonymous point mutationsType of mammary tumorsPositions of mutationChanges of amino acidsPolyPhen predictionBenign4765 G \>CE1589 QProbably damagingMalignant3619 A \>GT1207 ABenignMalignant4006 G \>AV1336 IProbably damaging. The prediction results showed that the 4765 G \>C that leads to the E1589Q substitution was probably damaging. The 4006 G \>A mutation that leads to V1336I substitution was probably damaging. The 3619 A \>G that leads to T1207A substitution was benign.

Methylated CpG sites detected in malignant canine mammary tumor
---------------------------------------------------------------

DNA methylation status of the 5′ flanking region of BRCA1 was analyzed by bisulfite sequencing. PCR successfully amplified the target fragments ([Fig. 3A](#fig_003){ref-type="fig"}Fig. 3.Methylation status of the 5′ flanking region of *BRCA1*. Panel A: bisulfite PCR results; M: DNA molecular weight marker. Using bisulfite-modified DNA (bDNA) as the template, the target fragment was successfully amplified. Using unmodified DNA (nDNA) as the template, the target fragment was not amplified, which indicated the specificity of the bisulfite primers. Panel B: the methylation status of normal mammary tissues. Panel C: the methylation status of the malignant tumor sample with methylated CpG sites. In panels B and C, each row of circles represents the methylation status of CpG sites obtained from one plasmid clone. The position of each CpG site relative to translation start (ATG) is shown. Open circles indicate the unmethylated CpG sites. Filled circles indicate the methylated CpG sites. Three clones of each sample were sequenced. As shown in panel B, all CpG sites were unmethylated in normal mammary tissues. As shown in panel C, the first four CpG sites were detected with methylation in one malignant mammary tumor sample.). The sequencing results of different clones are shown in [Fig. 3B and 3C](#fig_003){ref-type="fig"}. No methylated CpG site was found in clones representing benign and normal canine mammary tissues ([Fig. 3B](#fig_003){ref-type="fig"}), whereas, one clone representing a malignant mammary tumor sample was detected with four methylated CpG sites, representing a methylation rate of 1/15 (6.7%) ([Fig. 3C](#fig_003){ref-type="fig"}).

DISCUSSION {#s3}
==========

After the canine BRCA1 gene was cloned, only limited data exist indicating its relationship with canine breeds and canine mammary tumors. In the study conducted by Tsuchida *et al.*, microsatellite polymorphism was demonstrated in intron 14 of the canine BRCA1 gene \[[@r29]\]. In several recent reports, single nucleotide polymorphisms (SNPs) of canine BRCA1 gene were found to correlate with canine mammary tumors. Borge *et al.* identified 64 SNPs in 11 genes including BRCA1 in canine mammary tumors \[[@r3]\]. In their report, they found one SNP in the coding region of BRCA1, which was a synonymous SNP \[[@r3]\] that generally does not alter the structure of the proteins. However, some synonymous SNPs alter RNA folding and may therefore have an impact on protein translation \[[@r14]\]. In the report by Borge *et al.*, the dogs used for the study were from eight different breeds (4 dogs of each breed) without a history of mammary tumors. In the present study, dogs with mammary tumor were used in the experiment, and normal dogs were used as a control. In the normal dog mammary tissue, no nucleotide variations were detected, indicating that genetic variations might be associated with mammary tumorigenesis.

Enginler *et al.* identified 12 SNPs of *BRCA1* and *BRCA2* in canine mammary tumors \[[@r5]\]. In their report, two SNPs were identified in intron 8 of *BRCA1*, and two other SNPs were identified in the coding region of *BRCA1* in canine mammary tumors \[[@r5]\]. These two SNPs in the coding region of *BRCA1* were also synonymous \[[@r5]\]. In addition, their study indicates a variation in the 5′ UTR, intron 8 and exon 9 of *BRCA1*, but no data are available on the other coding exons. The present study detected point mutations leading to alteration of the amino acids in *BRCA1* corresponding to altered protein function. In addition, all of the coding exons were sequenced to find the genetic variations. Similar to the present study, dogs with mammary tumor were used by Enginler *et al.* and Sun *et al.* to identify three SNPs in the 5′- and 3′-UTRs of *BRCA1* in canine mammary tumors \[[@r25]\]. In the report by Sun *et al.*, one non-synonymous SNP was found in the coding region of BRCA1 in canine mammary tumors, which leads to a substitution of Ala1851Thr \[[@r25]\]. The present study contributes four additional point mutations in the coding region of *BRCA1* with a promising role in canine tumor biology. The above process utilized the direct sequencing technique with the limitation that only the dominant mutation sites could be detected.

The BRCA1 C-terminal (BRCT) is highly conserved among human, mouse and canine \[[@r26]\]. In human, there were two BRCT repeat domains in the C-terminal region \[[@r32]\]. The BRCT repeat domain (amino acids 1560-1863) is an important domain that functions to activate transcription \[[@r18]\]. The 4702G \>T mutation detected in the present study, leads to the loss of the BRCT repeat domain. In humans, loss of BRCT function was an important mechanism that promoted tumorigenesis \[[@r26]\]. Considering the high homology of BRCT domains between humans and canine, the truncated BRCA1 might probably lose its function without the C-terminal \[[@r10]\].

The 3619A \>G mutation altered the amino acid residue in BRCA1 from threonine to alanine residue (T1207A). Threonine is a hydrophilic amino acid, while alanine is a hydrophobic amino acid. The substitution might therefore affect the structure of the canine BRCA1 protein. The 4006G \>A mutation substituted the valine residue with isoleucine residue (V1336I) in the BRCA1 polypeptide. Both valine and isoleucine are hydrophobic amino acid. The molecular weight of valine is similar to the molecular weight of isoleucine. However, there is another trans-activation domain (AD1) of BRCA1 (amino acids 1293-1558), which functions in concert with BRCT domain \[[@r11], [@r12]\]. The (V1336I) substitution might affect the trans-activation function of AD1 domain.

In order to further predict the effects of the three point mutations with amino acids substitutions, we used the online analysis software "PolyPhen". The results showed that the 4006 G \>A and 4765 G \>C mutations were probably damaging. The 3619 A \>G mutation was benign. The prediction results implied that two of the three point mutations might cause loss of function of the BRCA1 protein and thereby play a major role in canine mammary tumorigenesis.

In humans, DNA methylation in the promoter region is the most important mechanism responsible for the down regulation of BRCA1 in breast cancer. In human sporadic breast tumor, the methylation rate of BRCA1 promoter ranged from 14.3% to 29.8% \[[@r16], [@r22], [@r33]\]. Previous studies indicate that the expression of BRCA1 was altered in canine mammary tumors as compared with normal mammary tissues \[[@r13], [@r20]\]. The underling mechanism of such a change is not yet elucidated. In this study, one out of fifteen (about 6.7%) malignant canine mammary tumors was found with four methylated CpG sites in the 5′ flanking region of BRCA1 gene. In humans, two CpG sites with methylation were found to affect the expression of BRCA1 \[[@r22]\]. Though the methylation rate was lower in the present study, the methylation mechanism might work in canine BRCA1 regulation.

In conclusion, four novel point mutations were found in the coding sequence along with a methylated CpG island in the 5′ flanking region of BRCA1 in canine mammary tumors, which might alter the function of BRCA1 as a tumor suppressor. The data provide newer insights in understanding the mechanism of BRCA1 mediated regulation of canine mammary tumorigenesis.
